Printer Friendly
The Free Library
19,585,946 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Acrongenomics, Inc. Announces Closing of $4,000,000 Private Placement to Fund Ongoing Operations.


ATHENS, Greece -- Acrongenomics, Inc. (OTCBB OTCBB

See OTC Bulletin Board (OTCBB).
:AGNM) a publicly traded research and development nanobiotechnology company pioneering the development of uniquely advanced nano-molecular diagnostics, today announced the closing of the 1,000,000 share private placement financing at $4.00 per share as of Friday December 16th 2005. Acrongenomics will use the net proceeds Net Proceeds

The amount received after all costs are deducted from the sale of a piece of property or security.

Notes:
In the case of an investor selling a security, net proceeds represent the proceeds from the sale minus any trading costs (i.e. commissions).
 for the ongoing development of the Nano-JETA platform as well as general corporate purposes.

"The success of this financing illustrates a strong confirmation of our approach, giving us the opportunity to focus on delivering advanced nanotechnology nanotechnology: see micromechanics.
nanotechnology

Manipulation of atoms, molecules, and materials to form structures on the scale of nanometres (billionths of a metre).
 research to the life sciences industry. By putting together our scientific excellence and strong financial base, we have managed to complete this private placement financing earlier than expected," said Constantine Poulios, Acrongenomics' Vice President.

Acrongenomics also announces that it is proceeding to obtain an independent evaluation of its technology from a certified See certification.  reference laboratory.

About Acrongenomics, Inc.

Acrongenomics, Inc. is a research and development nanobiotechnology company pioneering the development of uniquely advanced nano-molecular diagnostics for the Life Sciences Industry. The Company is seeking to establish its proprietary nanotechnology platform as a global standard in Molecular In Vitro Diagnostics In vitro diagnostic (IVD) tests are medical tests conducted in a test tube, or more generally in a controlled environment outside a living organism. In vitro means in glass in Latin. .
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 22, 2005
Words:186
Previous Article:Median Price of a Home in California at $548,400 in November, Up 16.2 Percent from Year Ago; Sales Decrease 11.2 Percent.
Next Article:Strategy X, Inc. Announces Development of Multi-Million Dollar Proprietary Homeland Security Modeling and Simulation Performance Based Software.
Topics:



Related Articles
Golden Valley Mines Ltd.: Private Placement with Quebec Based Investment Fund for Proceeds of CDN$200,000.
Dia Bras Announces Conditional Exchange Approval Of $4 Million Private Placement.
ECU Silver Mining Inc.-Press Release.
Summus Closes Private Placement Led by Liberty Associated Partners; Proceeds to Accelerate Direct-to-Consumer Portal Strategy.
Strateco Resources to Raise $1,920,250 in Private Placement Funding.
MacMillan Gold Announces $2,000,000 Private Placement.
MacMillan Gold Has Raised $2,500,000 In Private Placement.
Bioxel Updates Information on Private Placement.
Bioxel Pharma Completes a Private Placement of $4.7M.
Acrongenomics Inc. Completes US $1,155,000 Private Placement.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles